Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Vivoryon Therapeutics AG ( (GB:0R3M) ).
Vivoryon Therapeutics announced significant progress in its kidney disease drug development, with a meta-analysis revealing that varoglutamstat significantly improves kidney function, particularly in diabetic patients. The company also strengthened its patent portfolio and nominated a new QPCT/L inhibitor for inflammatory and fibrotic diseases, enhancing its industry positioning.
More about Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, with a market focus on inflammatory, fibrotic, and kidney diseases.
YTD Price Performance: -1.51%
Average Trading Volume: 4,434
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €51.87M
See more insights into 0R3M stock on TipRanks’ Stock Analysis page.